M ycobacterium avium complex (MAC) predominantly consists of M avium and Mycobacterium intracellulare and is the most frequent etiology of pulmonary disease caused by nontuberculous mycobacteria (NTM). 1,2 M avium and M intracellulare cannot be differentiated through traditional physical and biochemical tests. 1 Most laboratories and studies report these species as M avium-intracellulare or MAC because they are considered to be highly similar, and the clinical features of patients who are infected with these two species are considered indistinguishable. [3] [4] [5] [6] MAC lung disease does not always require antibiotic therapy, and the decision to initiate therapy is 
Radiologic Examination Data Analysis
We classifi ed chest radiography and high-resolution CT scan fi ndings obtained at the time of diagnosis as showing either fi brocavitary disease or nodular bronchiectatic disease. When the disease did not belong to either the fi brocavitary form or the nodular bronchiectatic form, it was deemed unclassifi able. 18, 19 Patient Management Data Analysis MAC lung disease may progress slowly. Furthermore, patients may not require treatment or may require combination antibiotic therapy. After this information was discussed with the patients, an observation period of at least 6 to 12 months without antibiotic treatment usually was implemented. When the disease was clearly recognized as progressive, the patients received combination antibiotic therapy. In patients with serious symptoms and advanced or progressive radiographic abnormalities, antibiotic therapy was initiated immediately. 15 Disease progression was determined by observing patients with MAC lung disease until combination antibiotic therapy was initiated. 20 All the patients who began antibiotic therapy received standardized combination antibiotic therapy, which consisted of oral clarithromycin, rifampin, and ethambutol. 1, 2 Streptomycin IM was administered in patients with severe disease. 15 Sputum conversion was defi ned as three consecutive negative cultures within 6 months, and the time of conversion was defi ned as the date of the fi rst negative culture. 15 A favorable microbiologic response was defi ned as a treatment duration of . 12 months and sputum conversion within 12 months. Therefore, patients who received antibiotic therapy for , 12 months were excluded from treatment outcome analysis.
Statistical Analysis
All data are presented as medians and interquartile ranges for the continuous variables and as numbers (percentages) for the categorical variables. The data were compared using Student t test for the continuous variables and x 2 test or Fisher exact test for the categorical variables.
The Kaplan-Meier method was used to estimate the cumulative rate for initiating antibiotic therapy. The log-rank test was used to test for a signifi cant difference between the curves. To determine whether M avium or M intracellulare was associated with disease progression, we performed univariable and multivariable Cox proportional hazard regression analyses. In the multivariable Cox regression model, a priori age, sex, BMI, sputum smear status, and disease type were controlled to compare the adjusted hazard rates between M avium and M intracellulare .
A multiple logistic regression analysis was used to identify the independent prognostic factors associated with unfavorable outcomes to antibiotic therapy. The variables, including species, dose reduction of clarithromycin, combined use of streptomycin for Ն 8 weeks, surgical resection, and the a priori potential confounding factors, were added to a multiple logistic regression model in which an unfavorable microbiologic response was the outcome variable. All statistical analyses were performed using SAS, version 9.1 software (SAS Institute Inc); a two-sided P , .05 was considered signifi cant.
Results

Clinical Features of MAC Lung Disease
During the 10-year period, 590 patients with MAC lung disease were identifi ed. The etiologic organisms included M avium in 323 patients (55%) and based on the potential risks and benefi ts for individual patients. 1, 7 Immediate treatment usually is recommended for the fi brocavitary form of MAC lung disease because of progressive lung destruction, whereas the nodular bronchiectatic form of MAC lung disease demonstrates variable disease progression. 1, 7 A substantial proportion of patients with the nodular bronchiectatic form of MAC lung disease do not have progressive or severe disease; therefore, they can be closely monitored without long-term antibiotic therapy. 8 Currently, M avium and M intracellulare are grouped together as MAC, and the advantage of species differentiation is unclear. 1, 2 Limited and confl icting data are available regarding the value of species differentiation between M avium and M intracellulare . [9] [10] [11] Therefore, little is known about the differences in the clinical features, disease progression, and responses to treatment between M avium and M intracellulare lung disease. MAC lung disease is becoming more common in Korea. [12] [13] [14] In this study, we compared the clinical features and prognoses of patients with M avium and M intracellulare lung disease who had been given this diagnosis within the past 10 years.
Materials and Methods
Study Population
Consecutive patients with MAC lung disease who were given the diagnosis between January 2000 and December 2009 were identifi ed using the database of the NTM Registry of Samsung Medical Center (a 1,950-bed referral hospital in Seoul, South Korea). 12, 15 The data from January 2008 to December 2009 are being used in an ongoing prospective observational cohort study to investigate NTM lung disease. 16 This study protocol was approved by the institutional review board of the Samsung Medical Center (IRB approval 2011-10-076).
During this 10-year period, 683 patients were given a diagnosis of MAC lung disease. All met the diagnostic criteria for NTM lung disease according to the guidelines of the American Thoracic Society. 1 After 93 patients with a history of previous NTM lung disease were excluded, 590 patients without a history of prior treatment of NTM lung disease were enrolled in this study.
Microbiologic Examination Data Analysis
Medical records included sputum smears and mycobacterial cultures, which had been performed using standard methods. 12, 15 Records described NTM species that were identifi ed using a polymerase chain reaction-restriction fragment length polymorphism method based on the b -subunit of RNA polymerase gene rpoB . 17 This genotypic method could accurately discriminate M avium and M intracellulare . At our institution, this method was used for the entire study period.
The sputum samples were obtained on two or more occasions after the initial presentation. When NTM other than M avium and M intracellulare were recovered more than twice during the follow-up period, the patients were reclassifi ed as having mixed infection and excluded from the study.
(64% vs 74%) in patients with M intracellulare lung disease ( P , .001) ( Table 1 ) .
Progression to the Initiation of Antibiotic Treatment
The median follow-up duration did not differ between the patients with M avium lung disease (39 months) and those with M intracellulare lung disease (38 months, P 5 .910). During the follow-up period, the proportion of patients who required combination antibiotic therapy was higher among those with M intracellulare lung disease ( P , .001) ( Fig 1 ) . The cumulative rate for initiating antibiotic therapy at 24 months in patients with M intracellulare lung disease was 58% (95% CI, 52%-64%) vs 42% (95% CI, 36%-47%) in patients with M avium lung disease ( P , .001).
These differences remained signifi cant after an adjustment using Cox regression for differences in age, sex, BMI, sputum smear status, and radiologic type. M intracellulare infection was an independent prognostic factor in the progression to the initiation of antibiotic treatment (adjusted hazard ratio [HR], 1.36; 95% CI, 1.09-1.70; P 5 .007) ( Table 2 ). In addition, patients with positive sputum smears (adjusted HR, 1.43; 95% CI, 1.13-1.81; P 5 .003) and those M intracellulare in 267 (45%). Other MAC member species, such as Mycobacterium colombiense , were not found during the study period. All patients were HIV negative.
As shown in Table 1 , patients with M intracellulare lung disease typically were older than patients with M avium lung disease (64 years vs 59 years, P 5 .002) and more likely to have a history of TB treatment (51% vs 31%, P , .001) and idiopathic pulmonary fi brosis (6% vs 1%, P , .001). Respiratory symptoms such as cough (84% vs 74%, P 5 .005), sputum (81% vs 73%, P 5 .023), and weight loss (6% vs 3%, P 5 .035) were more common in patients with M intracellulare lung disease than in those with M avium lung disease.
The erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level at the time of diagnosis were signifi cantly higher in patients with M intracellulare lung disease than in those with M avium lung disease (ESR, 33 mm/h vs 25 mm/h [ P 5 .001]; CRP, 0.29 mg/dL vs 0.14 mg/dL [ P , .001]). Patients with M intracellulare lung disease typically had a higher percentage of sputum smear results that were positive for acid-fast bacilli (56% vs 38%, P , .001). The fi brocavitary form was more common (26% vs 13%) than the nodular bronchiectatic form ( Table 3 ) .
Discussion
This study examined . 500 patients with MAC lung disease and focused primarily on the clinical relevance of species differentiation between M avium and M intracellulare . In the present cohort of patients with MAC without HIV infection, M avium and M intracellulare differed in the clinical features, disease progression, and treatment response to antibiotic therapy. Patients with M intracellulare lung disease exhibited a more severe and advanced clinical presentation at the time of diagnosis, were more likely to receive antibiotic treatment during the follow-up period, and had lower treatment response rates than those with M avium lung disease.
The epidemiologic data suggest that the incidence and prevalence of MAC infections are increasing in many countries. [21] [22] [23] [24] [25] [26] M avium and M intracellulare are infrequently differentiated in clinical practice and the medical literature; however, these mycobacteria exhibit a signifi cantly different pathogenicity and biology. 11 The majority of AIDS-related MAC infections are due to M avium , and disseminated M avium infections typically occur only after the CD4 1 T-lymphocyte count is , 50/ m L, which suggests that cellular immunodefi ciency is a risk factor for M avium (but not for M intracellulare ) infection. 27 A previous study using an animal model suggested that M intracellulare was more virulent than M avium . 28 We found that patients with M intracellulare lung disease are more likely to have had fi brocavitary disease; therefore, more patients have smear-positive sputum specimens. The ESR and serum CRP level were with the fibrocavitary form (adjusted HR, 2.84; 95% CI, 2.14-3.78; P , .001) were more likely to receive antibiotic treatment. Conversely, older patients were less likely to receive antibiotic treatment during the follow-up period (adjusted HR, 0.76; 95% CI, 0.61-0.95; P 5 .018).
Treatment Outcomes
Combination antibiotic therapy was initiated in 330 patients by the end of August 2011. Of these patients, 35 who received antibiotic therapy for , 12 months and who were still being treated were excluded from further analysis. Of the remaining 295 patients (158 with M intracellulare lung disease, 137 with M avium lung disease), the overall favorable microbiologic response was signifi cantly lower in patients with M intracellulare lung disease (88 of 158 [56%]) than in those with M avium lung disease (102 of 137 [74%], P 5 .001).
After adjusting for potential confounding factors, the fi nal multiple logistic regression model revealed that bacterial virulence plays an important role in the development and progression of invasive MAC infection; however, a direct comparison of virulence between M avium and M intracellulare was not available. 30, 31 In the present study, M intracellulare infection was newly identifi ed as an important predictor of progression to the initiation of treatment among patients with MAC lung disease. To our knowledge, this analysis is the fi rst to demonstrate that the treatment response rate is lower in M intracellulare lung disease than in M avium lung disease in patients who received the same standardized combination antibiotic therapy. Previous clinical studies that evaluated the treatment effi cacy of macrolide-based antibiotic regimens or assessed the prognostic factors for MAC lung disease did not distinguish between M avium and M intracellulare lung disease. 2, 3, 32, 33 Our previous small-scale study suggested that the treatment response rate was slightly lower in patients with M intracellulare than in those with M avium lung disease, but this was not statistically signifi cant. 15 The current study included approximately 300 patients with MAC lung disease who received combination antibiotics for . 12 months. We demonstrated that M intracellulare infection was independently associated with an unfavorable microbiologic response. Interestingly, a previous study of 51 patients with macrolide-resistant MAC lung disease revealed that the majority (77%) of isolates were M intracellulare rather than M avium , and M intracellulare strains were more common among the isolates from fi brocavitary disease than among those from nodular bronchiectatic disease. 5 The present study has several limitations. First, it was conducted at a single center; therefore, it was not representative of Korea because of referral bias. Second, the decision to initiate long-term combination antibiotic therapy did not depend on fi rmly signifi cantly increased in patients with M intracellulare lung disease compared with those with M avium lung disease. Chronic infl ammation may have contributed to a more severe and advanced clinical presentation at the time of diagnosis in patients with M intracellulare lung disease.
MAC lung disease does not always require antibiotic therapy. 1, 7 However, treatment of MAC lung disease may require long-term antibiotic treatment. Patients may meet the diagnostic criteria but not have progressive or severe disease; therefore, these patients are closely monitored with regular sputum collection. 1 In a recent study, long-term antibiotic therapy was administered to , 20% of patients in the United States and about 50% of patients in Canada and South Korea after being given a diagnosis of MAC lung disease. 15, 24, 29 Even after disease recognition, physicians may opt for a wait-and-see approach before prescribing antibiotics because of the reported low treatment effi cacy and high drug toxicity. 24 This approach is the treatment practice at our hospital. During the study, antibiotic treatment typically was started after a diagnosis in patients with the fi brocavitary form of MAC lung disease; however, antibiotic treatment was frequently initiated in patients with the nodular bronchiectatic form of MAC lung disease after the recognition of disease progression during follow-up.
Patients may remain in a stable condition for years or may progress rapidly. 1,2 However, there are few studies in which patients with well-defi ned characteristics exhibit disease progression. 8 Currently, there is no consensus regarding the treatment of patients with MAC lung disease. A study in Japan found that 60% of patients with nodular bronchiectatic MAC lung disease demonstrated disease progression, whereas 40% of patients were stable during a mean observation period of 28 months. 8 Several studies suggest established objective criteria. However, we believe that the probability of referral to our hospital and the deci sion to initiate antibiotic therapy were distributed equally among patients with M avium vs M intracellulare lung disease. In summary, patients with M intracellulare lung disease exhibited a more severe and advanced clinical presentation at the time of diagnosis and had a worse prognosis than patients with M avium lung disease in terms of disease progression and treatment response. Therefore, species differentiation between M avium and M intracellulare may have prognostic and therapeutic implications. Additional studies are warranted to verify these fi ndings.
